A drug candidate, based on pioneering UCL and Moorfields Eye Hospital research and currently under development by SIFI S.p.A., has been found to be highly effective in treating a rare sight-threatening eye infection in a new international clinical trial.
Edwards, Medtronic post low-risk TAVR data, allaying fears of market disruption
Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Edwards Lifesciences and Medtronic reported